Trial Profile
A Multi-Center, Phase II, Open Label, Single-Arm Trial of Durvalumab and Epacadostat in Patients With Unresectable, Recurrent, and Metastatic EBV+ NPC
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Epacadostat (Primary)
- Indications Brain metastases; Nasopharyngeal cancer
- Focus Therapeutic Use
- 22 Oct 2020 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.
- 22 Oct 2020 Planned primary completion date changed from 1 Apr 2021 to 1 Apr 2022.
- 22 Oct 2020 Planned initiation date changed from 1 Feb 2020 to 1 Dec 2020.